NYSE:MRK
Merck Stock News
$126.09
-3.40 (-2.63%)
At Close: May 28, 2024
Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO
03:23pm, Thursday, 04'th Jan 2024
Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.
Why the Market Dipped But Merck (MRK) Gained Today
07:33pm, Wednesday, 03'rd Jan 2024
In the latest trading session, Merck (MRK) closed at $114.77, marking a +1.35% move from the previous day.
Revenge of the Boring Stocks! Dividends Are Sexy Again.
04:00pm, Wednesday, 03'rd Jan 2024
It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.
MDA Breakouts In Best Year Ever: New Picks For Week 1 - 2024
10:48am, Sunday, 31'st Dec 2023
The Weekly MDA Breakouts completed the best year since this model was released on Seeking Alpha in 2017. In 2023, 125 picks gained over 5% and 65 picks gained over 10% in their measured week, with sim
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
10:00am, Friday, 29'th Dec 2023
The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
09:15am, Friday, 29'th Dec 2023
Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.
Why Merck (MRK) Outpaced the Stock Market Today
07:32pm, Wednesday, 27'th Dec 2023
In the most recent trading session, Merck (MRK) closed at $107.98, indicating a +0.33% shift from the previous trading day.
Wall Street's top 5 stocks with the biggest upside in 2024
09:00am, Tuesday, 26'th Dec 2023
With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in t
Merck: Smart Value For Potentially Strong Total Returns
09:20am, Monday, 25'th Dec 2023
Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Keytruda has been a major revenue driver for MRK, with continued sales growth and potential for extend
Merck: An Excellent Dividend Grower With Strong Annual Total Return Potential
07:30am, Monday, 25'th Dec 2023
Merck has managed to thrive throughout its 132-year corporate history. The company posted healthy sales and non-GAAP EPS growth in the third quarter. Merck boasts an A+ credit rating from S&P on a sta
Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth
12:24am, Monday, 25'th Dec 2023
Merck & Co. is a drug manufacturer that has outperformed the healthcare ETF and the S&P 500 over the past decade. The company's pharmaceutical segment, including products like Keytruda and vaccines, c
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
09:00am, Sunday, 24'th Dec 2023
As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It's a time when astute investors set
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
10:32am, Thursday, 21'st Dec 2023
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
7 Best Dow Jones Stocks to Buy for Conservative Investors
09:12am, Thursday, 21'st Dec 2023
With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative investors appears overly cautious. Don't get me wrong
US FDA declines to approve Merck's chronic cough drug
06:01pm, Wednesday, 20'th Dec 2023
The U.S. Food and Drug Administration (FDA) has declined to approve Merck's drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two years.